Clinical trial / 2014
A 21-day macrobiotic Ma-Pi 2 diet led to greater reductions in blood glucose and HbA1c than a standard recommended diet in type 2 diabetes patients.
A randomized, controlled, open-label 21-day trial compared the macrobiotic Ma-Pi 2 diet with standard recommended diets in patients with type 2 diabetes. After adjusting for age, gender, baseline BMI, and physical activity, patients on the Ma-Pi 2 diet showed significantly greater reductions in FBG (95% CI: 1.79; 13.46), PPBG (95% CI: 5.39; 31.44), and HbA1c (95% CI: 1.28; 5.46). The Ma-Pi 2 group also had significantly greater reductions in insulin resistance, total cholesterol, LDL cholesterol, LDL/HDL ratio, BMI, body weight, and waist and hip circumference, while the control group showed a significantly greater reduction in triglycerides.
- Study type
- Randomized, controlled, open-label, 21-day trial
- Who was studied
- Patients with type 2 diabetes
- What was measured
- Changes in fasting blood glucose (FBG) and post-prandial blood glucose (PPBG)
THE PAPER
The effect of the macrobiotic Ma-Pi 2 diet vs. the recommended diet in the management of type 2 diabetes: the randomized controlled MADIAB trial.
Soare A, Khazrai YM, Del Toro R, Roncella E, Fontana L, Fallucca S, Angeletti S, Formisano V, Capata F, Ruiz V, Porrata C, Skrami E, Gesuita R, Manfrini S, Fallucca F, Pianesi M, Pozzilli P. Nutr Metab (Lond), 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.